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ABSTRACT

Biopharmaceutic and Pharmacokinetic Studies of Sucrose Acetate Isobutyrate
as an Excipient for Oral Drug Delivery
by
Martin Ray Tant
Sucrose acetate isobutyrate (SAIB), a randomly substituted sucrose approximating sucrose
diacetate hexaisobutyrate, is produced by Eastman Chemical Company for a variety of
applications. SAIB is widely used in the food industry as a weighting agent to disperse flavoring
oils in primarily citrus-based soft drink beverages. Additionally, SAIB is currently being
marketed by another company as a parenteral drug delivery system. The studies reported here
focused on investigating SAIB as an excipient, or delivery vehicle, for use in oral delivery of
several drugs, including ibuprofen, saquinavir, and clarithromycin. Dissolution experiments
were conducted using both ibuprofen and caffeine, and results suggest that SAIB can be used
in dosage forms to control release rate. Pharmacokinetic studies in which laboratory rats were
dosed with formulations containing drugs such as ibuprofen, saquinavir, and clarithromycin
suggest that SAIB may act to reduce animal-to-animal variability in drug concentration profiles
in some cases, and that it may also enhance gastroretention of the dosage forms. Finally,
dosage form imaging studies suggest but do not reliably confirm that SAIB may aid in
promoting gastric retention, which would make its use in dosage form formulation beneficial for
administration of drugs whose action is intended to occur in the stomach.
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CHAPTER 1
INTRODUCTION
The general goal of oral drug administration is to simply, safely, and effectively deliver a
drug to the target tissue, or biospace, within the body at the concentration and for the duration
required to achieve the desired clinical or pharmacologic effect. The rate and extent to which
the drug of interest reaches the biospace is a direct result of (1) the kinetics of the following
processes: liberation from the dosage form; dissolution; absorption into systemic circulation;
distribution to the target tissue; metabolism; and excretion; and (2) the dose size and
frequency of dosing. The study of the rates of the processes given in (1) above encompasses
the sciences of biopharmaceutics and pharmacokinetics (Van de Waterbeemd et al. 2003).
Biopharmaceutics concerns the physicochemical properties of the drug and dosage form and
involves such factors as (1) the stability of the drug within the dosage form, (2) the release of
the drug from the dosage form, (3) the rate of dissolution of the drug, and (4) the systemic
absorption of the drug (Shargel et al. 2005). Pharmacokinetics involves the study of the rates
of absorption, distribution, metabolism, and excretion, as well as the interrelationships of these
complex and dynamic processes (Ritschel et al. 2004). Pharmacodynamics, on the other hand,
describes the rate at which the drug causes the pharmacologic effect once it has reached the
biospace in sufficient concentration to induce the effect (Tozer and Rowland 2006). One way to
explain the difference between pharmacokinetics and pharmacodynamics is that
pharmacokinetics describes the effect of the body on the drug while pharmacodynamics
describes the effect of the drug on the body.
The LADMER (liberation, absorption, distribution, metabolism, excretion, and response)
acronym is often used to define the processes of interest in oral drug delivery (Shargel et al.
2005). The schematic diagram given in Figure 1 illustrates in a simplified way the dynamic
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interrelationships between these complex processes and shows the general boundaries between
the sciences of biopharmaceutics, pharmacokinetics, and pharmacodynamics. From a physical,
chemical, and mathematical understanding of the biopharmaceutics and pharmacokinetics of a
particular drug dosage form, as well as the pharmacodynamics of the specific drug, one can
predict the dose and dosing frequency required to maintain the drug level needed in the
biospace that will result in the desired clinical or pharmacologic effect.

Biopharmaceutics
Drug release
and dissolution

Absorption

Liberation

Pharmacokinetics
Drug in systemic
circulation

Distribution

Drug in
tissues

Elimination

Pharmacodynamics

Excretion and

Pharmacologic or
clinical effect

Metabolism

Response
Figure 1. Dynamic relationship between the drug, dosage form, and pharmacologic effect
(adapted from Shargel et al. 2005)

The general goal of pharmacokinetics is to describe these processes mathematically
from the point of drug dissolution in the intestinal lumen to systemic circulation. Because
elimination, which occurs by both metabolism and excretion, and distribution of the drug
between the blood and tissue are continuous, these processes must be considered in addition
to absorption. Basically, there are 3 different classes of approaches (Fournier 2007) for
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mathematically describing the time-dependent plasma concentration of a drug administered to
the body: (1) the compartmental approach, (2) the physiological approach, and (3) the modelindependent approach. The compartmental approach is now very highly developed and is quite
well described within the texts by Ritschel and Kearns (2004) and by Shargel et al. (2005).
More recent approaches to quantitatively modeling pharmacokinetic processes have been
physiologically based. In these approaches the processes of the different physiological systems
are modeled mathematically, often requiring the use of higher mathematics than is required for
more simplistic approaches to pharmacokinetics. The field of physiologically based
pharmacokinetic modeling is currently evolving (Mancheras and Iliadis 2005, Reddy et al. 2006).
The third approach for modeling pharmacokinetic data can be classified as phenomenological,
as no attempt is made to describe the actual processes involved – only the resulting data. All of
the pharmacokinetic modeling performed in the present work follows the compartmental
approach.
Sucrose acetate isobutyrate (SAIB), a randomly substituted mixture of sucrose esters
approximating sucrose diacetate hexaisobutyrate, is produced by Eastman Chemical Company
(Kingsport, TN) under the trademark Sustain. It is available in a variety of compositions for
different applications. The most common application of SAIB is that of a weighting agent to
disperse flavoring oils in primarily citrus-based soft drink beverages. SAIB acts as a densityadjusting agent to prevent separation and to maintain a cloudy dispersion throughout the
beverage product, and is approved as a food additive in more than 40 countries. Due to the
potential risk of acute and chronic exposure to this compound by humans, extensive toxicology
studies using various animal subjects, including humans, were conducted beginning in the early
1960s. Many of these are summarized in 2 reviews published in 1998 in the journal Food and

Chemical Toxicology. Here, Reynolds and Chappel (1998) reviewed toxicity studies published
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prior to 1988, while Reynolds (1998) reviewed studies of the metabolism and pharmacokinetics
of SAIB in rats, dogs, monkeys and humans. In the same issue appear articles concerning
subchronic toxicity of SAIB in rats and dogs (Proctor and Chappel 1998), toxicity studies in the
cynomolgus monkey (Blair and Chappel 1998), toxicity and carcinogenicity studies in the rat
and the mouse (Mackenzie et al. 1998a), reproductive studies in the rat and teratology studies
in the rat and rabbit (Mackenzie et al. 1998b), the effect of SAIB on the hepatobiliary function
of humans (Chiang et al. 1998), and, finally, the genotoxic effects of SAIB (Myhr et al. 1998).
In the early 1970s, Reynolds and Chappel (1998) confirmed the finding of Morgareidge
(1965) that ingestion of SAIB by dogs results in an increase in the weight of the liver and serum
alkaline phosphatase levels resulting from interference of SAIB with biliary excretion. Further
studies in dogs, which were reviewed by Proctor and Chappel (1998), suggest that effects of
SAIB on the hepatobiliary system of the dog can appear after only one low dose. However, this
effect is rapidly reversible following cessation of SAIB ingestion, suggesting that it is likely to be
a pharmacological effect rather than a toxic one. Similar effects were not found in rats and
monkeys.
The results of the toxicity studies of Blair and Chappel (1998) on the cynomolgous
monkey showed that animals ingesting up to 2400 mg/kg body weight of SAIB per day showed
no signs of specific toxicity, including a lack of the effects on the hepatobiliary function
observed in dogs.
Hensley (1975) and Orr et al. (1976) conducted studies on humans. Hensley (1975)
dosed human volunteers at a level of 10 mg/kg body weight per day for 14 days, while Orr et
al. (1976) dosed a different sample of human volunteers at levels of 7 and 20 mg/kg body
weight per day for the same time period. The 20 mg/kg per day dosage regimen is 4 times
greater than the lowest dosage used in dogs which resulted in increases in BSP
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(bromosulfophthalein) and ICG (indocyanine green). Chiang (1998) conducted further studies
on the effect of SAIB on the hepatobiliary function of humans. These studies suggest that daily
SAIB dosages of 20 mg/kg body weight in humans do not result in changes in biliary function as
in the case of dogs.
Myhr et al. (1998) conducted a series of different in vitro genotoxicity assays that
examined the interaction of SAIB with genetic material from metabolically competent liver cells
at concentrations of 0.024 to 1000 μg/ml. These tests, which are capable of detecting point
mutations, chromosomal damage, and the induction of DNA lesions, were negative, indicating
that SAIB has no damaging effects on DNA. These workers concluded that, because of these
negative results, and the fact that Tennant et al. (1987) had previously established that these in

vitro genotoxicity assays are sensitive tests for potential carcinogenicity in vivo, SAIB is
therefore not genotoxic and should not contribute to the dietary intake of mutagens.
MacKenzie et al. (1998) conducted a 3-generation reproductive and teratogenicity study
of Fischer 344 rats receiving oral dosages of SAIB up to 2.0 g/kg for 10 weeks. A separate
teratogenicity study was conducted on New Zealand white rabbits at oral dosages of up to 1.2
g/kg body weight. These workers concluded that, even at these high doses of SAIB,
there were no observed effects in either case.
In a series of patents, Southern Biosystems made claims for inventions using SAIB as a
parenteral depot delivery system under the trademark SABER (sucrose acetate isobutyrate –
extended release), currently marketed by Durect (Tipton and Ewing 1996; Tipton and Holl
1996; Gibson et al. 1999). SABERTM can be classified as a biodegradable in situ-forming depot
(ISFD) system (Tipton and Dunn 2000; Hatefi and Amsden 2002).

Sullivan et al. (1998)

tested a SABER system for release of progesterone and estradiol in seasonally anovulatory
mares. Genentech, Inc. made claim for a specific formulation for parenteral dosing of growth
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hormone, specifically human growth hormone (Okumu 2001). In 2002, Hatefi and Amsden and
then Matschke et al. published reviews of injectable dosage forms that act as in situ forming
drug delivery or depot delivery systems. Tipton (2003) published a review of the use of SAIB
as an in situ forming drug delivery system.
Because SAIB is a mixed ester, it is not crystallizable and thus exists as an extremely
highly viscous liquid. SAIB is very difficult to handle in its neat form due to both its high
viscosity (>100,000 cP at 25°C) and high degree of tackiness. However, a 90%/10%
SAIB/ethanol solution possesses such a dramatically lower viscosity (770 cP at 25°C) that it is
injectable. In the SABER system, the drug of interest is dissolved in the low-viscosity SAIBethanol solution and injected into tissue. Upon injection, the ethanol rapidly diffuses away,
leaving the high-viscosity, hydrophobic SAIB in situ depot containing the drug. The drug then
diffuses out of the SAIB and into the surrounding tissue and the SAIB depot is slowly
metabolized. As a result of that work, the question arose as to whether or not SAIB has
potential as an excipient for oral drug delivery.
The absorption of most drugs delivered orally occurs primarily in the small intestine and
the rate of absorption is dependent upon both the solubility and the permeability of the drug.
Solubility might be enhanced by chemical means, e.g. by using a cosolvent that acts to
solubilize the drug in the gastrointestinal environment (Li et al. 1999). The effective
permeability of the drug through the gut wall may be enhanced by decreasing the degree of
ionization of the drug (Palm et al. 1999; Kobate et al. 2008), by blocking metabolizing enzymes
(Bai et al. 1996; Yusuf et al. 2000), or by blocking transporters that extrude the drug back into
the intestinal lumen (Huisman et al. 2001,2003; Constantinides and Wasan 2006; Collnot et al.
2007). Thus the possibility exists that any enhancement of absorption of a drug in an SAIB
delivery system could be due to effects on any of these processes. Effects on drug liberation

16

and solubility are easily tested, while effects on transport or metabolism require specific in vitro
testing such as Caco-2 transport studies and microsomal metabolic studies (Tucker et al. 2001;
Cummins et al. 2003). Identification of particular transporters and/or enzymes involved may be
accomplished using recombinant transporters/enzymes or microsomal systems that differentially
express the proteins of interest (Crespi et al. 2000).
An additional way that drug absorption might be enhanced is by using gastroretentive
dosage forms (GRDFs) that prolong the lifetime and integrity of the delivery system within the
stomach (Chawla et al. 2003; Hoffman et al. 2004; Streubel et al. 2006). This approach has
been shown to be particularly effective for drugs having a narrow distribution window, such
drugs being well absorbed in the proximal small intestine but to a lesser extent in the distal.
Examples of such drugs are levodopa, metformin, furosemide, and ciprofloxacin. GRDFs have
been shown to be effective for furosemide and ciprofloxacin, e.g. Depomed's RFD/ciprofloxacin
recently marketed drug product, Ciprofloxacin GR™, for treatment of urinary infections.
Gastroretentive dosage forms may also be the desirable delivery approach for certain drugs
whose action is intended to occur, not in tissue, but within the gastric environment, e.g. the
treatment of Helicobacter pylori in the stomach using clarithromycin (Conway et al. 2005;
Bardonnet et al. 2006). In this latter case, gastric retention extends the duration of exposure of
the drug to the bacteria in their gastric habitat and thus the exposure time of the bacteria to
the minimum inhibitory concentration of antibiotic. Such an increase in the duration of
exposure reduces frequency of dosing, improves compliance (fewer dosages), and greatly
enhances the probability of eradication.
In this work, I hypothesized that sucrose acetate isobutyrate may enhance the
absorption of some drugs and that this enhancement might occur by one or more of the
following mechanisms: (1) modification of drug liberation from the dosage form, (2)
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enhancement of drug solubility, (3) gastroretention of the dosage form, or (4) modification of
the absorption mechanism. The question regarding mechanisms (1) and (2) above were
addressed using dissolution studies and mechanisms (3) and (4) were addressed through
pharmacokinetic studies and dosage form imaging studies in live animals. These studies
reported here were directed at determining whether or not SAIB might be a useful excipient for
oral drug delivery and, if so, which of the mechanisms does it affect.

18

CHAPTER 2
METHODS AND MATERIALS

Dissolution Experiments
Ibuprofen
Sucrose acetate isobutyrate (SAIB), whose structure is

was supplied by Eastman Chemical Company in the form of Sustane SAIB ET-10 containing
approximately 90 wt% SAIB and 10 wt% ethanol. As mentioned in the previous chapter, this
particular form of SAIB was used because of its lower viscosity and ease of handling. In
addition, ibuprofen, being soluble in ethanol, is easily dissolved in this system. Ibuprofen,
having the chemical structure

was supplied in crystalline form by the Performance Chemicals and Intermediates Business
Organization of Eastman Chemical Company.
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Ibuprofen was initially dissolved in the Sustane SAIB ET-10 at 12.5 wt%. At this
concentration the SAIB ET-10 was nearly saturated. Higher concentrations were made by
adding additional ethanol to the mixture to solubilize the ibuprofen. Two additional
compositions were then made: one containing 16.8% ibuprofen in a system of 82.6%
SAIB/17.4% EtOH and 22.6% ibuprofen in a system of 79% SAIB/21% EtOH. Both solutions
were essentially saturated with ibuprofen. Amounts of these 3 different Ibuprofen/SAIB/ EtOH
solutions were then transferred to capsules for dissolution testing using a USP-1 dissolution
apparatus (illustrated in Figure 1), specifically a Distek Dissolution System, in a 6.8 pH buffered
solution. Exact amounts were measured to give a concentration of 50.0 ppm when fully
dissolved in the dissolution apparatus. Three additional capsules were prepared: one empty
capsule, one capsule containing only ibuprofen, and one capsule containing only SAIB. The
capsules were placed in separate baskets and simultaneously immersed in different baths
containing 6.8 pH buffer maintained at 37°C. The baskets were rotated at 50 rpm and 10 mL
aliquots were removed at specific time intervals during the dissolution process.

Figure 2. The USP-1 Dissolution Apparatus of the U.S. Pharmacopeia containing buffer solution
and a rotating basket containing the dosage form
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The samples were then analyzed immediately after collection using a Hewlett-Packard 8452A
Diode Array Spectrophotometer. The analysis followed the procedure for ibuprofen outlined in
the U.S. Pharmacopeia, which stipulates that the absorption at 280 nm be subtracted from the
absorption at 266 nm. Clearly from Figure 3 below, one can see that the absorption at 266nm
varies greatly with concentration while that at 280nm is much less a function of concentration.
Plotting the difference in absorption at these two wavelengths vs. concentration gives a linear
relationship as shown in Figure 4.

0.14
6.8 pH Buffer
0.12

10 ppm
20 ppm

Absorbance

0.1

30 ppm
40 ppm

0.08

50 ppm
Gelcap in 6.8 pH
Buffer
Saturated SAIB

0.06

0.04

0.02

0
200

220

240

260

280

300

320

340

360

Wavelength (nm)

Figure 3. Absorption spectra for 6.8 pH buffer, standard solutions of ibuprofen in 6.8 pH buffer,
and a capsule dissolved in the buffer

21

Ibuprofen Concentration (ppm)

60

50

40

30

20

y = 644.91x - 0.4035
R2 = 0.9998

10

0
0

0.01

0.02

0.03

0.04

0.05

0.06

0.07

0.08

Absorption @ 266nm - Absorption @ 280nm

Figure 4. Calibration plot for analysis of ibuprofen during dissolution in 6.8 pH buffer

Caffeine
Caffeine, having the chemical structure

and carboxymethylcellulose (CMC), i.e.
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0.09

were compounded together at a 25/75 weight ratio and caffeine/CMC/SAIB (not including
ethanol) formulations were compounded at a 25/25/50 weight ratio. Ethanol was added to the
formulation to facilitate mixing. Because SAIB ET-10 was used to prepare these formulations,
calculations of weights to be used had to include allowance for the additional ethanol present.
The formulations were then lyophilized overnight to remove ethanol and were reweighed to
determine the exact composition and the amount of ethanol lost. They were then packed into
size 9 porcine hard gelatin capsules, obtained from Torpac, for the dissolution study.
For the dissolution experiments, a 10 mL vial containing 9 mL of buffer solution was
placed into a reciprocating water bath at 37°C for 5 minutes to reach temperature. A capsule
was then placed into the vial and the bath was cycled at 60 cycles/min. Then 0.5 mL aliquots
were removed at specific time increments, filtered, and stored. 0.5 mL of buffer was then
replaced into the vial and it was returned to the reciprocating water bath. Following the
dissolution and sample collection procedure, 200 µL were removed from the solution taken at
each time increment, transferred to a UV 96-well plate, and analyzed at 275 nm. A calibration
curve, shown in Figure 5, was constructed and used to determine concentration as a function of
the time following introduction of the capsule to the dissolution vial.
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Figure 5. Calibration plot for analysis of caffeine during dissolution in 1.2 pH buffer
(absorbance at 275nm)

Pharmacokinetic Experiments

Male Sprague-Dawley rats were used for all pharmacokinetic studies. The animals were
housed in temperature-controlled rooms with, generally, three rats to a cage, having controlled
12-hr light and dark cycles in the ETSU Division of Laboratory Animal Resources on the College
of Medicine campus. Water was provided during the entire period. Some studies included a
12-hr fasting period prior to dosing while some did not, the specifics of which are described
below. All studies were reviewed and approved by the ETSU Committee on Animal Care.
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Ibuprofen
For the pharmacokinetic (PK) studies with ibuprofen, SAIB was not formulated into the
dosage form. For this initial PK study on rats, Sustain SAIB MCT containing 80 wt% SAIB and
20 wt% medium chain triglycerides was manually compounded into standard rat chow.
Eighteen male Sprague-Dawley rats were included in the study and the rats were divided into 3
groups of 6 rats each. Group I and II rats were fed a normal diet of rat chow until and
throughout dosing and blood collection. Group III rats were fed a diet of ground rat chow
containing 4 wt% SAIB and 1 wt% MCT for 48 hrs before dosing and throughout the blood
collection. Although animals are typically fasted prior to commencement of PK studies, these
animals were not fasted as it was desired to determine the effect of diet (SAIB vs. no SAIB) on
the pharmacokinetics of ibuprofen. Group I rats were dosed intravenously at the beginning of
the pharmacokinetic experiment and Group II and Group III rats were dosed orally at about 10
mg/Kg as 0.45 mL. Approximately 125 µL of blood were collected into mini-capillary collection
tubes containing EDTA dipotassium salt (SAFE-T FILL; RAM Scientific Inc., Yonkers, NY USA),
placed on dry ice, and kept frozen until analysis. Samples were analyzed by HPLC/MS by Mr.
James L. Little at Eastman Chemical Company and data were analyzed using a GraphPad Prism,
Version 5.0 software package.

Saquinavir
Two different saquinavir formulations were made for oral dosing: (1) a formulation
containing 25 wt% saquinavir and 75 wt% CMC and (2) a formulation containing 25 wt%
saquinavir, 25 wt% CMC, and 50 wt% SAIB. Animals were fasted beginning 12 hours prior to
commencement of the pharmacokinetic study. Blood samples were collected in the same
manner as for the ibuprofen study described earlier, and samples were analyzed for saquinavir
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by Dr. Michael Wempe by HPLC/MS/MS at Eastman Chemical Company, Kingsport, Tennessee.
Data were analyzed using the GraphPad Prism 4.0, Version 4 software package.

Clarithromycin
Two different clarithromycin formulations were made: (1) a formulation containing about
15 wt% clarithromycin and 85 wt% CMC and (2) a formulation containing about 20 wt%
clarithromycin, 40 wt% CMC, and 40 wt% SAIB. Pharmacokinetic studies were conducted as
described for saquinavir and samples were analyzed via LC/MS/MS by Dr. Michael Wempe for
clarithromycin, decladinose clarithromycin (product of acid-catalyzed hydrolysis in the stomach),
and the metabolites demethyl clarithromycin and hydroxyl clarithromycin. Standard curves for
clarithromycin and decladinose clarithromycin are shown in Figures 6 and 7, respectively. Data
were analyzed using the GraphPad Prism 4.0, Version 4 software package.

Dosage Form Imaging Studies in Live Animals
In order to determine if dosage forms containing SAIB persist in the gastrointestinal
tract for longer periods of time thus leading to extended release of the drug in vivo,
formulations containing (1) 25 wt% barium sulfate and 75 wt% CMC and (2) 25 wt% barium
sulfate, 25 wt% CMC, and 50 wt% SAIB were made and packed into capsules in the same
manner as for the pharmacokinetic studies. Animals were orally dosed, restrained, and then Xrayed in the animal facility at ETSU as a function of time following dosing. Images were
collected using a Pinnacle Systems Dazzle imaging board and a personal computer and were
visually compared to determine qualitative differences in rate of dispersion of the dosage form.
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Statistical Analysis

Statistical analysis of the data for this work was accomplished using the JMP® statistical
software package. A one-way analysis of variance (ANOVA) was used to compare groups that
received different types of a dosage form containing a particular drug. Tukey-Kramer HSD
(Honestly Significant Difference) comparisons were used to compare groups when the ANOVA
was inconclusive. In cases where groups being compared had large differences in variability,
we used a variance-stabilizing transformation to account for this variability and comparisons
were made of the transformation to ensure that conclusions reached were not simply based on
noise in the data.

28

CHAPTER 3

RESULTS

Dissolution Experiments
Ibuprofen
Ibuprofen was chosen as a model drug to begin investigating how sucrose acetate
isobutyrate affects the release and dissolution kinetics of a drug when compounded into an oral
dosage form. For these initial studies we used an SAIB/ethanol mixture without removing the
ethanol from the dosage form.

It is well known that when such a system is injected

parenterally, the ethanol rapidly diffuses into surrounding tissue leaving the drug dissolved
within the SAIB (Tipton 2003). The result is a depot delivery system from which the drug
slowly diffuses out into the surrounding tissue.

As described in the previous chapter,

dissolution experiments for ibuprofen in 6.8 pH buffer involved measuring the absorption at 266
and 280nm and subtracting the latter from the former. These experiments resulted in the plots
shown in Figure 8. Using the calibration curve from Figure 4 and accounting for withdrawal of
buffer without replacement and for the presence of gelcap and/or SAIB, the concentration-time
curves shown in Figure 9 were obtained.
Each of these dosage forms contained the same amount of ibuprofen – enough to give a
50.0 ppm solution of ibuprofen at full dissolution. Clearly the dissolution of the dosage form
containing only ibuprofen in a gelcap reached 50.0 ppm at long times. The other 3, in which
ibuprofen was dissolved in various compositions of SAIB and ethanol, did not, suggesting that
not all of the ibuprofen was released from the dosage form even after about 3 days. These
results will be discussed more thoroughly in Chapter 4.
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Figure 8. Absorbance at 266nm minus absorbance at 280nm during the dissolution in 6.8 pH
buffer for several dosage forms
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Figure 9. Concentration profiles vs. time for dissolution of ibuprofen in 6.8 pH buffer
from several different dosage forms
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Caffeine
While the dissolution work using solutions of ibuprofen in SAIB/ethanol provided useful
information, further investigations of drug dissolution from solid drug forms containing SAIB
were performed.

Because carboxymethylcellulose (CMC) is often used as a binder in drug

dosage forms, and we indeed did use it in pharmacokinetic work to be described later, we
included it as well – primarily in the controls.

Two dosage forms were made: (1) one

containing 25% caffeine and 75% CMC as a control, and (2) one containing 25% caffeine, 50%
SAIB, and 25% CMC.

Experiments were performed as described previously, and the

measurements of absorption vs. time are shown in Figure 10 below.
Converting absorbance to concentration using the calibration curve (Fig. 5) leads to the
plot shown in Figure 11, where the results are shown with 2 different time scales. Clearly the
concentration of caffeine reaches much higher values for the caffeine/SAIB/CMC dosage form
than for the caffeine/CMC dosage form. This can be partially explained by the fact that the
caffeine/SAIB/CMC dosage form contained more caffeine (7.45 mg) than the caffeine/CMC
dosage form (4.525 mg). It should also be noted that the calibration curve is very flat in the
high-concentration region and that concentration values are thus not as reliable in this region.
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Figure 10. Absorbance at 275 nm vs. time for dissolution of caffeine in 1.2 pH buffer from 2
different dosage forms – one containing SAIB and one without
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buffer
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The dissolution results reported here on ibuprofen and caffeine dissolution experiments,
both with and without SAIB as part of the dosage form, suggest that the inclusion of SAIB is
observed to decrease the rate of release and/or dissolution of the drug. These results will be
discussed more thoroughly in the Discussion section.

Pharmacokinetic Experiments
Ibuprofen
Figures 12-14 show plasma concentration-time profiles for rats in the three groups of six
rats each dosed with ibuprofen in the following ways, respectively: Fig. 12 - rats fed a normal
diet and dosed intravenously, Fig 13 – rats fed a normal diet and dosed orally, and Fig. 14 –
rats fed a normal diet with 4 wt % sucrose acetate isobutyrate blended into the food. Data
were fitted using an open one-compartment model, including elimination only for the
intravenously dosed rats and including both absorption and elimination for the orally dosed rats.
These equations are given as

C t   C 0  e  kel t

(1)

C t   B  e kel t  A  e  kt t

(2)

for the rats dosed intravenously and

for the rats dosed orally, where

C(t)

=

drug concentration in blood at time t

ka

=

absorption rate constant

kel

=

elimination rate constant

and A and B are constants. GraphPad Prism 5.0 was used to model the data. The models
converged for all experiments except rat #3 in Figure 14. Curve fits are shown in the figures
and kinetic parameters are shown in Tables 1-3.
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Although the open one-compartment model fit the data for many of the rats, the data
for others appear to follow an open 2-compartment model. This behavior is observed when the
kinetics of distribution between blood and other soft tissue, and distribution into deeper tissues,
occur at different rates. In this case the equations for intravenous and oral administration
become

C t   B  e

 ket

 A  e t

C t   B  e t  A  et  C 0 e kat

and

(3)
(4)

respectively, where

and

C(0)

=

initial drug concentration

α

=

distribution slope

β

=

overall elimination slope.

Such a model shows an initial rapid appearance of drug in the blood followed by a rapid
decrease resulting from both distribution into the deeper compartment, i.e. tissue, and
elimination through normal metabolic processes. As distribution into the tissue and
redistribution back into the blood reaches a steady state, elimination becomes the controlling
process, causing a decrease in drug concentration in the blood, and the concentration-time
slope changes.
For the open one-compartment model, C(0)=A=B, and thus these constants can be
easily compared to determine consistency between groups. A comparison of C(0), A, and B
obtained from the curve fits for each dosing method was conducted using a one-way analysis of
variance (ANOVA) in the JMP® 9.0.0 statistics package. This comparison is shown in Fig. 15.
The values of C(0), obtained from curve fits for the rats dosed intravenously are much more
tightly grouped than the values of A and B obtained from the curve fits for the rats dosed orally.
Due to the amount of variability in A and B for the rats dosed orally, a variance-stabilizing
transformation on C(0), A, and B was used to determine if there are significant differences
between the groups. Results of a Box-Cox transformation suggested that an inverse square
transformation should be performed on C(0), A, and B. The Tukey-Kramer HSD test on these
transformed results revealed that the means of the inverse square roots are not significantly
different. Thus, there is no difference between C(0), A, and B. These constants should be the
same for the open one-compartment model.
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Figure 12. Ibuprofen plasma concentration profiles for rats fed a normal diet and dosed
intravenously. Data were fitted using an open one-compartment intravenous model
(elimination only)
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Figure 13. Ibuprofen plasma concentration profiles for rats fed a normal diet and dosed orally.
Data were fitted using an open one-compartment oral model (absorption and elimination)
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Figure 14. Ibuprofen plasma concentration profiles for rats fed a diet consisting of rat chow
containing 4 wt% SAIB and dosed orally. Data were fitted using an open one-compartment oral
model (absorption and elimination)
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Table 1. Pharmacokinetic Parameters for Rats (Normal Diet) Dosed Intravenously with
Ibuprofen
IV1

IV2

Normal

Normal

Diet

Diet

Diet

Diet

Diet

Diet

C(0)

77.75

71.18

63.51

65.06

66.30

70.35

69.0±4.7

kel

0.954

1.391

1.292

1.095

1.217

1.111

1.18±0.14

R2

0.976

0.996

0.983

0.965

0.969

0.974

Parameter

IV3

IV4

Normal Normal

IV5

IV6

Normal Normal

Mean
±σ

Table 2. Pharmacokinetic Parameters for Rats (Normal Diet) Dosed Orally with Ibuprofen
Oral1

Oral2

Oral3

Oral4

Oral5

Oral6

Mean

Normal

Normal

Normal

Normal

Normal

Normal

±σ

Diet

Diet

Diet

Diet

Diet

Diet

A=B

264.6

11.78

17.58

16.57

21.02

71.43

67.2±90.8

ka

3.312

6.831

3.860

8.221

3.692

2.912

4.80±1.99

kel

2.473

0.482

0.772

0.496

0.729

1.138

1.02±0.69

R2

0.955

0.919

0.959

0.972

0.988

0.883

Parameter

Table 3. Pharmacokinetic Parameters for Rats (SAIB Diet) Dosed Orally with Ibuprofen
Oral1

Oral2

Oral3

Oral4

Oral5

Oral6

Mean

SAIB

SAIB

SAIB

SAIB

SAIB

SAIB

±σ

Diet

Diet

Diet

Diet

Diet

Diet

A=B

144.5

21.21

NC*

14.61

15.40

14.67

42.08±51.27

ka

3.867

33.03

NC*

6.761

4.098

5.378

10.63±11.25

kel

1.887

0.860

NC*

0.4746

0.455

0.507

0.84±0.55

R2

0.994

0.982

NC*

0.978

0.976

0.943

Parameter

* NC = No Convergence
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Comparisons for all pairs using Tukey-Kramer HSD
Level
Oral SAIB A
Oral
A
IV
A

Mean
0.21557135
0.19557205
0.12057238

Levels not connected by same letter are significantly different.

Figure 15. Results of statistical analysis of C(0), A, and B for ibuprofen obtained using the
open one-compartment model for (1) rats fed a normal diet and dosed intravenously and (2)
rats fed a normal diet and dosed orally, and (3) rats fed a diet containing 4 wt% SAIB and
dosed orally
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The elimination rate constants, kel, should be the same as well. Figure 16 shows the results of
a similar statistical analysis on the elimination rate constants for all 3 rat groups. A one-way
ANOVA of the data and a Tukey-Kramer HSD on the inverse square root were performed as
before. There were no differences observed for the 3 groups.
This statistical analysis was also performed on the integrated absorption rate constants,
ka, for each rat dosage group. A one-way ANOVA of the data and a Tukey-Kramer HSD on the
inverse square root were once again performed and the results are shown in Figure 17. In this
case, and inverse transformation of ka was used and the Tukey-Kramer HSD indicated that
there is no significant difference between the ka’s for ibuprofen absorption for the rats fed
different diets.
Finally, Figure 18 shows the results of the Tukey-Kramer HSD for the means of areas
under the ibuprofen plasma concentration-time curves. The long horizontal line of the green
diamond indicates the mean, the short horizontal lines indicate the standard error of the mean,
and the upper- and lower-most points of the diamond indicate the standard deviations. The
latter 2 are the pooled standard errors and standard deviations. The results suggest that the
mean value of the area under the curve for the IV dosage form is significantly different from
the mean values for the 2 groups dosed orally. However, the mean for the 2 groups dosed
orally are not significantly different from each other.

Saquinavir
Figures 19 and 20 show the individual blood plasma concentration-time plots for rats
dosed with saquinavir/CMC dosage forms and 6 rats dosed with saquinavir/CMC/SAIB dosage
forms, respectively. We show these data individually for clarity. Figure 21 shows the open
one-compartment model fits of these data. Because there is so much scatter, we decided to
look at the data in a different way for this study. Figure 22 shows the mean values for the 6
rats in each of the 2 groups along with standard error of the means for each group at each
time. This figure suggested that the area under the curve for the dosage form containing SAIB
might be larger than that without SAIB. To investigate this we integrated the area under each
of the curves and calculated a mean AUC for each of the 2 groups. Conducting a one-way
analysis of variance and a Tukey-Kramer HSD, the results of which are shown in Figure 23, we
determined that there is no significant difference in the mean areas under the curves for the 2
groups of rats.
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Comparisons for all pairs using Tukey-Kramer HSD
Level
Kel Oral
Kel Oral SAIB
Kel IV

A
A
A

Mean
1.1238221
0.9718967
0.9270531

Levels not connected by same letter are significantly different.

Figure 16. Results of statistical analysis of elimination rate constant, Kel, for ibuprofen obtained
using the open one-compartment model for (1) rats fed a normal diet and dosed intravenously
and (2) rats fed a normal diet and dosed orally, and (3) rats fed a diet containing 4 wt% SAIB
and dosed orally
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Comparisons for all pairs using Tukey-Kramer HSD
Level
Mean
A
Ka Oral
0.24054890
Ka Oral SAIB A
0.17334904
Levels not connected by same letter are significantly different.

Figure 17. Results of statistical analysis of absorption rate constant, Ka, for ibuprofen obtained
using the open one-compartment model for rats dosed orally and (1) fed a normal diet or (2)
fed a diet containing 4 wt% SAIB and dosed orally
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Comparisons for all pairs using Tukey-Kramer HSD
Level
IV
A
Oral
B
Oral SAIB B

Mean
53.246667
35.575000
29.350000

Levels not connected by same letter are significantly different.

Figure 18. Results of statistical analysis of areas under the ibuprofen plasma concentrationtime curve obtained using the open one-compartment model for (1) rats fed a normal diet and
dosed intravenously and (2) rats fed a normal diet and dosed orally, and (3) rats fed a diet
containing 4 wt% SAIB and dosed orally
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Figure 19. Saquinavir concentration profiles for the 6 rats dosed with saquinavir/CMC dosage
forms
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Figure 20. Saquinavir concentration profiles for the 6 rats dosed with saquinavir/CMC/SAIB
dosage forms
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Figure 21. Aggregate plots showing: (a) the concentration of saquinavir for rats dosed with
saquinavir/CMC dosage forms and (b) the concentration of saquinavir for rats dosed with
saquinavir/CMC/SAIB dosage forms
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Figure 22. Saquinavir mean concentration profiles for the 6 rats dosed with either
saquinavir/CMC or saquinavir/CMC/SAIB dosage forms. Shown are the means and standard
error of the means for all rats of each population
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Comparisons for all pairs using Tukey-Kramer HSD
Level
Saquinavir CMC/SAIB A
Saquinavir CMC
A

Mean
3213.3333
2481.4000

Levels not connected by same letter are significantly different.

Figure 23. Results of statistical analysis of areas under the saquinavir plasma concentrationtime curve for rats dosed either (1) saquinavir/CMC or (2) saquinavir/CMC/SAIB
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Clarithromycin
According to Wibawa et al. (2003), clarithromycin is hydrolyzed in an acidic environment
(e.g. the stomach) to decladinose clarithromycin as shown in Figure 24. The pharmacokinetic
studies that we conducted on clarithromycin included blood analysis for both clarithromycin and
decladinose clarithromycin.
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Figure 24. Acid catalyzed hydrolysis of clarithromycin to decladinose clarithromycin
Figure 25 shows the mean clarithromycin blood plasma concentration-time plots for
three rats dosed with clarithromycin/CMC dosage forms and 3 rats dosed with
clarithromycin/CMC/SAIB dosage forms. Figure 26 show the concentration-time profiles for
decladinose clarithromycin. Clearly there is more variability in the results for the rats dosed
with clarithromycin/CMC than the clarithromycin/CMC/SAIB dosage forms. Several statistical
analyses of the areas under the curves for these 2 groups were performed, including a one-way
analysis of variance and a Tukey-Kramer HSD. A t-test revealed a P-value of 0.747. These are
shown in Figure 27 for clarithromycin. All the results confirm that there is no difference
between the areas under the curves. The results for decladinose clarithromycin are shown in
Figure 28. In this case, a natural log transformation was performed for the Tukey-Kramer HSD.
The areas under the curves were found to be statistically significant for decladinose
clarithromycin, the concentrations being much higher for the clarithromycin/CMC/SAIB dosage
forms than for the clarithromycin/CMC forms.
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Figure 25. Clarithromycin concentration-time profiles for rats dosed orally with and without
SAIB (n = 3 ± SEM)

Decladinose
Clarithromycin (ng/mL)

1200

Decladinose
Clarithromycin

1000

AUC0-24 = 1136 ± 104 ng ·h/mL

800

Decladinose
Clarithromycin + SAIB

600

AUC0-24 = 3571 ± 470 ng ·h/mL

400
200
0
0

4

8

12

16

20

24

Time (h)
Figure 26. Decladinose clarithromycin plasma concentration-time profiles for rats dosed orally
with clarithromycin both with and without SAIB (n = 3 ± SEM)

50

Comparisons for all pairs using Tukey-Kramer HSD
Level
Clar CMC
A
Clar CMC/SAIB A

Mean
1692.8333
1483.6667

Levels not connected by same letter are significantly different.

t Test
Clar CMC/SAIB-Clar CMC
Assuming unequal variances
Difference
-209.2 t Ratio
Std Err Dif
579.6 DF
Upper CL Dif
1911.4 Prob > |t|
Lower CL Dif
-2329.7 Prob > t
Confidence
0.95 Prob < t

-0.36088
2.42175
0.7473
0.6263
0.3737 -2000 -1000

0 500

1500

Figure 27. Results of statistical analysis of areas under the clarithromycin plasma
concentration-time curves for rats does with either (1) clarithromycin/CMC or (2)
clarithromycin/CMC/SAIB

51

Comparisons for all pairs using Tukey-Kramer HSD
Level
Declad CMC/SAIB
Declad CMC

A
B

Mean
8.3581940
7.0269531

Levels not connected by same letter are significantly different.

Figure 28. Results of statistical analysis of areas under the decladinose clarithromycin plasma
concentration-time curves for rats does with either (1) clarithromycin/CMC or (2)
clarithromycin/CMC/SAIB
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Rat liver microsomal incubations performed at Eastman Chemical Company by Wempe
(2006) demonstrated that 3 metabolites are formed from clarithromycin as shown in Figure 29.
As a result of this work, both demethyl-clarithromycin and hydroxy-clarithromycin were also
monitored and their blood plasma concentration-time plots are shown in Figures 30 and 31,
respectively. For both of these metabolites, less variation again results from administration of
clarithromycin with SAIB but there are no statistically significant differences, as demonstrated
by the results shown in Figures 32 and 33.
The results of this study are consistent with the hypothesis that the formulation
containing SAIB is retained in the stomach for a longer period of time and also suggest that in
this particular study SAIB acts to decrease the animal-to-animal variability of drug concentration
profiles.

M = Clarithromycin
O

HO

OMe
OH

O

O

Oxidation

O

O
HO

N

HO
O

OMe

HO

O
O

OH

O

OH
O

O

O

N

HO

Oxidation

O
OMe

O

Demethylation

OMe

O

O

HO

OMe
OH

+

O

O

OH
HO

OMe

M1 = 14-OH-Clarithromycin

O

O

NH

HO
O
OMe

O

OH
O
O

O

N

HO

O

OH

M2 = N-Demethyl-clarithromycin

OMe

O

O

O

OH

M1A = Clarithromycin + O

Figure 29. In vivo metabolism from liver microsomal incubations

53

Demethyl Clarithromycin (ng/mL)

60
50

Clarithromycin dose
AUC0-24 = 266 ± 103 ng  h/mL

40

Clarithromycin + SAIB dose
AUC0-24 = 142 ± 29 ng  h/mL

30
20
10
0
0

4

8

12

16

20

24

Time (h)
Figure 30. Demethyl clarithromycin concentration-time profiles for rats dosed orally with
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Figure 31. Hydroxy-clarithromycin concentration-time profiles for rats dosed orally with
clarithromycin both with and without SAIB (n = 3 ± SEM)
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Comparisons for all pairs using Tukey-Kramer HSD
Level
Demeth CMC
A
Demeth CMC/SAIB A

Mean
266.45667
142.36667

Levels not connected by same letter are significantly different.

t Test
Demeth CMC/SAIB-Demeth CMC
Assuming unequal variances
Difference
-124.09 t Ratio
Std Err Dif
106.80 DF
Upper CL Dif
280.90 Prob > |t|
Lower CL Dif
-529.08 Prob > t
Confidence
0.95 Prob < t

-1.16187
2.311632
0.3512
0.8244
0.1756 -400

-200
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Figure 32. Results of statistical analysis of areas under the demethyl clarithromycin plasma
concentration-time curves for rats does with either (1) clarithromycin/CMC or (2)
clarithromycin/CMC/SAIB
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Comparisons for all pairs using Tukey-Kramer HSD
Level
Hyd CMC
A
Hyd CMC/SAIB A

Mean
10.925092
8.610617

Levels not connected by same letter are significantly different.

Figure 33. Results of statistical analysis of areas under the hydroxy clarithromycin plasma
concentration-time curves for rats does with either (1) clarithromycin/CMC or (2)
clarithromycin/CMC/SAIB.
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X-Ray Imaging Experiments
X-rays of rats dosed with (1) 25%BaSO4/75%CMC and (2) 25%BaSO4/
25% CMC/50%SAIB are shown in Figure 34. Images are presented sequentially so that time
moves from left to right and images from different groups can be compared directly at each
time. These x-rays show that the dosage form containing SAIB persisted up to 100 minutes,
while the dosage form that did not contain SAIB persisted only to 35 minutes. Had these been
the only 2 dosing experiments performed, one would conclude that dosage forms containing
SAIB retain their integrity for longer times. However, additional experiments were performed
with mixed results using different dosage forms and different rats. Some dosage forms
disappeared after relatively short times (~30 minutes), while others persisted to much longer
times (>100 minutes). However, these results do suggest that perhaps through improvements
in the design of SAIB dosage forms and in consistency of SAIB dosage form preparation, it may
be possible to create SAIB dosage forms that retain their integrity for longer periods of time.
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Pre-dosing (BaSO4/CMC)

2 min (BaSO4/CMC)

Pre-dosing (BaSO4/CMC/SAIB)

2 min BaSO4/CMC/SAIB

Figure 34. X-ray images showing the BaSO4/CMC dosage form (top) and BaSO4/CMC/SAIB
(bottom) in vivo as a function of time following oral dosing
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5 min (BaSO4/CMC)

10 min (BaSO4/CMC)

5 min (BaSO4/CMC/SAIB)

10 min BaSO4/CMC/SAIB

Figure 34 (continued). X-ray images showing the BaSO4/CMC dosage form (top) and
BaSO4/CMC/SAIB (bottom) in vivo as a function of time following oral dosing
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15 min (BaSO4/CMC)

20 min (BaSO4/CMC)

15 min (BaSO4/CMC/SAIB)

20 min BaSO4/CMC/SAIB

Figure 34 (continued). X-ray images showing the BaSO4/CMC dosage form (top) and
BaSO4/CMC/SAIB (bottom) in vivo as a function of time following oral dosing
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30 min (BaSO4/CMC)

40 min (BaSO4/CMC)

30 min (BaSO4/CMC/SAIB)

40 min BaSO4/CMC/SAIB

Figure 34 (continued). X-ray images showing the BaSO4/CMC dosage form (top) and
BaSO4/CMC/SAIB (bottom) in vivo as a function of time following oral dosing
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50 min (BaSO4/CMC)

50 min (BaSO4/CMC/SAIB)
Figure 34 (continued). X-ray images showing the BaSO4/CMC dosage form (top) and
BaSO4/CMC/SAIB (bottom) in vivo as a function of time following oral dosing
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75 min (BaSO4/CMC/SAIB)

100 min BaSO4/CMC/SAIB

Figure 34 (continued). X-ray images showing the BaSO4/CMC/SAIB in vivo as a function of time
following oral dosing
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CHAPTER 4
DISCUSSION
As discussed in Chapter 1, the processes involved in oral drug delivery are complex and
interdependent. Absorption of a chemical substance into the bloodstream for distribution to
various tissues of the body that contain the receptors that stimulate the pharmacologic
response cannot occur until the drug has been dissolved in the fluids of the intestinal lumen.
The amounts of drug administered and the rates of the processes of drug dissolution,
absorption, and distribution must therefore be quantified in order for drug delivery to be
understandable and predictable. As the goal of this work was to begin to gain an
understanding of how sucrose acetate isobutyrate might be used to control processes involved
in oral drug delivery, we focused on understanding various aspects of these processes for
several different drug and dosage systems – primarily dissolution and pharmacokinetics.

Dissolution Experiments
Ibuprofen
As described in Chapters 2 and 3, initial dissolution studies were conducted using
capsules containing ibuprofen dissolved in a solution of sucrose acetate isobutyrate and
ethanol. Figures 8 and 9 show the results of the dissolution experiments conducted on several
ibuprofen dosage forms. Figure 8 shows the absorption results of aliquots take from the
dissolution apparatus at different times following introduction into the apparatus and Figure 9
shows the calculated ibuprofen concentration. The upper curve in each figure, shown by blue
diamonds and dashed line, is that of the control sample – a capsule containing only ibuprofen
powder. In this case, the concentration of ibuprofen dissolved in the buffer is dependent upon
the kinetics of 2 consecutive processes: (1) the dissolution/disintegration of the capsule and
(2) the dissolution of the ibuprofen powder as it is exposed to the buffer solution. As
mentioned previously, all dosage forms contained precisely enough ibuprofen to give a 50.0
ppm solution at full dissolution. Clearly, for this dosage form, the ibuprofen powder had been
exposed to the buffer within the first 10 minutes after being introduced to the buffer as 35% of
the ibuprofen was in solution by that time. Therefore the capsule had dissolved/disintegrated
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enough to allow escape of the powder into the buffer solution within the first 10 minutes after
introduction to the dissolution bath. At 45 minutes into the dissolution experiment about 85%
of the ibuprofen was dissolved, and all of it was in solution within 6 hours. This sample
containing only ibuprofen powder thus provided an excellent control to compare with those
containing both ibuprofen and sucrose acetate isobutyrate. The dissolution of the dosage form
containing 12.5 wt% ibuprofen dissolved in 90%SAIB/10%EtOH is shown by red squares and
red dashed line. It would be assumed that release of the ibuprofen/SAIB/EtOH following
dissolution/disintegration of the capsule would occur at about the same time as for the control
sample. However, 6 hours into the dissolution experiment only about 18.3% of the ibuprofen
had been released into solution. Visual inspection of the dosage form revealed that the SAIB
remained together and attached to the rotating basket during the experiment. Clearly the
diffusion of the ibuprofen out of the SAIB is a relatively slow process. The other 2 curves
represent dissolution of dosage forms containing higher concentrations of ibuprofen (16.4 and
22.5 wt%). The amount of ethanol in these 2 dosage forms was higher in order to dissolve
more ethanol. The release rates for these 2 dosage forms were obviously virtually the same.
The conclusion from these experiments is that, while dissolution of ibuprofen at 6.8 pH is very
rapid, its release/dissolution rate can be controlled through design of the dosage form using
SAIB/ethanol as an excipient.

Caffeine
The initial dissolution experiments on ibuprofen used ethanol as a solvent for the SAIB
and the ibuprofen. Our next experiments, which were conducted on caffeine due to its stability
and solubility, did not use ethanol as a cosolvent. Instead, caffeine was compounded with a
mixture of SAIB and carboxymethylcellulose (CMC) as described in the experimental section.
The results of these experiments are shown in Figures 10 and 11. The absorbance at 275 nm
is shown as a function of time in Figure 10. The calibration curve shown in Figure 5 was then
used to convert absorbance to concentration, which is plotted in Figure 11. Similar to the
observation from the previous study on ibuprofen, caffeine from the dosage form compounded
with SAIB and CMC goes into solution more slowly than from the one in which caffeine was
compounded with CMC alone. As mentioned earlier, final concentration levels are much higher
for the caffeine/CMC/SAIB dosage form than for the caffeine/CMC dosage form because it
contained more caffeine (7.45 mg vs. 4.525). Also, concentrations above about 0.2 mg must
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be viewed with caution as the calibration curve becomes very flat in this concentration range
and small deviations in absorbance can have a very large effect on the calculated concentration.
The more interesting results of this experiment are, however, at very early times (<5 min) and
low concentrations (<0.2 mg/mL). Clearly, the dosage form containing SAIB releases caffeine
much more slowly than the dosage form that does not. In fact, the dissolution curve for the
dosage form containing SAIB is concave upward while the dissolution curve for the dosage form
that does not contain SAIB is concave downward. One can easily calculate an initial dissolution
rate for both dosage forms from the first data point obtained for each. At 1 min following
introduction of the dosage forms, the concentration of caffeine for the caffeine/CMC dosage
form is 0.11 mg/ml while that of the caffeine/SAIB/CMC dosage form is 0.0006 mg/ml. Even
accounting for the difference in the amount of caffeine present in the 2 dosage forms, the
dissolution rate of caffeine from the caffeine/CMC dosage form was initially many times faster
than the dissolution of caffeine from the caffeine/CMC/SAIB dosage form. Visual observation of
the dissolution experiments confirmed that the caffeine/CMC/SAIB dosage forms maintained
their integrity longer, as was observed in the ibuprofen dissolution experiments, thus allowing
the drug to be released more slowly into the buffer solution. Clearly, by manipulating the
relative amounts of drug, CMC, and SAIB one should be able to vary the release rate of the
drug from the dosage form and thus control how and to what extent the drug is released in the
body.

Pharmacokinetic Experiments
Ibuprofen
Initial pharmacokinetic experiments were performed using ibuprofen as the drug.
Instead of using a dosage form containing SAIB compounded with the drug, it was initially
decided to feed the rats a diet either containing or not containing SAIB as a component. In this
way the rats that were fed a diet containing 4 wt% SAIB would always have SAIB throughout
their digestive system while the rats fed a normal diet would not. This would then serve as a
test of whether or not SAIB might improve absorption of ibuprofen. As stated earlier, blood
samples were analyzed by Mr. James L. Little of Eastman Chemical Company. Figures 12-14
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show the results of the pharmacokinetic study. Data were fitted using an open onecompartment model with elimination only for the intravenously dosed rats and using an open
one-compartment model with both absorption and elimination for the orally dosed rats.
The calculated pharmacokinetic parameters obtained using GraphPad 5.0 are tabulated
in Tables I-III along with R2 values for each curve fit and mean values and sample standard
deviations for each set of rats. It should be noted that the values of the parameters for the rats
dosed intravenously are much more reproducible than for the animals dosed orally. Figure 15
shows the results of a one-way analysis of variance and a Tukey-Kramer HSD for the preexponential constants for all of the curve fits. The results confirm that there is no difference
between C(0), A, or B for the different rat groups, as should be the case. The elimination rate
constant, kel, for all 3 rat groups should be the same as well. The same statistical analyses
were performed on kel and, as shown in Figure 16, kel is not statistically different for the 3
groups. The same 2 statistical comparisons were performed on the ka values for the 2 rat
groups that were dosed orally, one being fed an SAIB diet and the other fed a normal diet.
These results are shown in Figure 17 and indicate that there is no difference in the absorption
rate constant for these 2 groups, as should be the case.
The total amount of drug absorbed from an oral dosage is typically calculated as the
area under the concentration-time curve and then compared with area under the curve
calculated for the intravenously dosed rats. This was done using the trapezoidal rule approach
in GraphPad Prism 5.0 and the results are shown in Figure 18 along with the results of the
Tukey-Kramer statistical analysis. It was found that there is a statistical difference between the
rat group dosed intravenously and the 2 rat groups dosed orally, with the IV-dosed rats
absorbing more ibuprofen since all of the drug was injected into the circulatory system.
However, there was no statistically significant difference in the total amount of drug absorbed
between the 2 rat groups dosed orally and thus the SAIB diet had no discernible effect on drug
absorption.

Saquinavir
Because the inclusion of SAIB in the diet had no detectable effect upon absorption of
ibuprofen in rats, it was decided to investigate SAIB as an actual component of the dosage form
itself and to compare the pharmacokinetics of a drug in rats dosed with such a dosage form to
the pharmacokinetics of the drug in rats dosed with a dosage form not containing SAIB.

67

Saquinavir was chosen as the model drug for this study and the measured blood concentration
levels following oral dosing are shown in Figures 19 and 20. Clearly there is a great deal of
scatter in the results. It is interesting, however, that high saquinavir blood plasma
concentration levels are maintained for both dosage groups for up to 3 days. Figure 21 shows
the compiled results with curve fits assuming an open one-compartment model. Again, the
scatter is great and no real conclusion can be drawn from the data. If the data within each of
the 2 groups are compiled together we get more data points at each time and can analyze it
statistically. Calculating standard errors of the mean for each group at each time increment
separately leads to Figure 22. Lines are drawn to connect the means and standard errors are
shown. The only difference between the 2 curves occurs at longer times where the rats dosed
with dosage forms containing SAIB appear to maintain higher blood concentration levels of
saquinavir. This result indicates the potential of SAIB as a possible sustained release agent.
Further manipulation of the dosage form composition should be carried out to investigate this
potential. These data were analyzed further by calculating the areas under the concentrationtime curves for each rat and applying a Tukey-Kramer HSD comparison. These results are
shown in Figure 23 and show that there is no difference in the areas under the curves for the 2
rat groups. Therefore, we were not able to determine an effect of having SAIB as a component
of the dosage form on the total absorption of saquinavir.

Clarithromycin
The most interesting pharmacokinetic study carried out as part of this work was
conducted on clarithromycin. As stated previously, an acidic environment such as that found in
the stomach is expected to catalyze clarithromycin to decladinose clarithromycin. Figures 25
and 26 show the blood concentration levels of clarithromycin and decladinose clarithromycin,
respectively, following dosing for 2 groups of rats dosed with clarithromycin dosage forms
containing SAIB or not. Figure 25 shows that, while there is not statistical difference in blood
level concentrations at times up to 6 hours, beyond that time there is a statistically higher blood
concentration level of clarithromycin for the rats dosed with dosage forms containing SAIB.
This supports the previously discussed saquinavir results that suggested a possible sustained or
prolonged release of drug from the dosage forms containing SAIB. Areas under the
concentration-time curves were again calculated and compared. The results shown in Figure 27
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reveal that, although the pharmacokinetics of clarithromycin is apparently different, the total
amount of clarithromycin absorbed by the 2 rat groups cannot be differentiated.
The results presented in Figure 26 show that the blood concentration of decladinose
clarithromycin, which would likely be formed in the acidic environment of the stomach, is
always higher for the rats dosed with dosage forms containing SAIB. The Tukey-Kramer HSD
comparison, as shown in Figure 28, reveals that these rats produced much more of the
decladinose form, suggesting that the SAIB dosage forms may be retained in the stomach for
longer periods of time than dosage forms that do not contain SAIB. This could obviously be
useful for a drug such as clarithromycin, as it is widely used for treatment of gastric

Helicobacter pylori, and gastric retention of the drug could maximize exposure to the bacteria
and thus be beneficial.
Blood concentrations of the metabolites demethyl clarithromycin and hydroxyl
clarithromycin are shown in Figures 30 and 31, respectively. These amounts indicate a portion
of the clarithromycin that has been absorbed and metabolized by the body. The Tukey-Kramer
HSD comparison for the areas under the curves are shown in Figure 32 and 33 for the demethyl
and hydroxy forms, respectively.

It was found that the differences between the blood levels

resulting from oral dosage via an SAIB-containing dosage form and one not containing SAIB are
are not statistically significant. However, there is clearly less variation for the SAIB dosage
forms. This result was also observed for clarithromycin itself. Apparently, SAIB imparts an
improved level of control to the release of clarithromycin in the body therefore rendering
concentration levels of the drug itself, as well as the metabolites demethyl clarithromycin and
hydroxyl clarithromycin, potentially more predictable.

X-Ray Imaging Experiments
As described earlier, rats were dosed with capsules containing (1) 25%BaSO4/75%CMC
and (2) 25%BaSO4/25% CMC/50%SAIB. X-ray images were obtained as a function of time
after dosing to follow break-up and dispersion of the dosage forms in the gastrointestinal
system. The dosage forms are clearly observable following dosing and persist for a variety of
durations. However, the length of time that they are observable by x-ray is highly variable and
does not seem to be related to whether or not SAIB is a component of the dosage form.
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Hence we have not been able to determine a difference in gastrointestinal integrity and
longevity for dosage forms prepared with and without SAIB from this work. However, it is
important to point out the fact that the dosage form not being observable by this method is not
proof that it does not retain some integrity. We do believe that by improvements in the design
of dosage forms and consistency in preparation, the longevity of dosage forms containing SAIB
may be enhanced.
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CHAPTER 5
CONCLUSIONS
These biopharmaceutic and pharmacokinetic studies of sucrose acetate isobutyrate in
experimental dosage forms were aimed at determining whether or not SAIB offers advantages
over other excipients in the oral delivery of drugs. Several different types of studies have been
conducted in an effort to address this question: (1) drug dissolution studies using ibuprofen
and caffeine as model drugs directed at determining if SAIB influences the release (liberation)
of dissolution of the drug; (2) pharmacokinetic studies in live laboratory rats using ibuprofen,
saquinavir, and clarithromycin as model drugs to determine if SAIB affects blood concentration
profiles of the drug following administration, e.g. by altering the rate or extent of drug release
or absorption; and (3) dosage form imaging studies in live laboratory rats directed at
determining whether or not SAIB improves dosage for integrity or promotes retention of the
dosage form in the stomach. The results of these studies led to several conclusions regarding
the effects of SAIB in oral drug delivery and, in other cases, suggest further potential work to
verify the results and conclusions.
The results of dissolution studies of ibuprofen/SAIB/ethanol dosage forms suggest that
this system may behave in a way similar to the reservoir system developed by Durect; i.e. once
the capsule is dissolved away, the SAIB/ethanol matrix acts as a depot delivery system, slowly
releasing ibuprofen over time. By varying the concentrations of drug, SAIB, and ethanol the
release rate of the drug can be controlled. The dissolution studies of caffeine/SAIB/CMC
(carboxymethylcellulose) and caffeine/CMC dosage forms suggest that the incorporation of SAIB
into the dosage form leads to a reduction in the initial release rate of the drug. Further studies
in this area should include different ratios of SAIB and CMC to learn more about the effects of
this ratio on release rate.
The pharmacokinetic studies of ibuprofen were directed at determining if the presence
of SAIB in the gastrointestinal tract of the rats would affect absorption of the drug. It was
found that the amount of ibuprofen absorbed was less for the rats fed an SAIB diet than for
those fed a normal diet. This suggests that SAIB simply being present in the digestive system
at the levels used does not result in enhancement of drug absorption in the case of ibuprofen.
Further studies could be directed at other types of drugs. Pharmacokinetic studies of
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saquinavir/SAIB/CMC and saquinavir/CMC dosage forms did not reveal a difference in the
overall amount of drug absorbed, but data results suggest that higher blood concentration
levels of saquinavir may be maintained at long times when SAIB is included as an excipient.
Further studies should be conducted to confirm this. Finally, pharmacokinetic studies of
clarithromycin/SAIB/CMC and clarithromycin/CMC dosage forms show that decladinose
clarithromycin levels in the blood are much higher in the rats dosed with dosage forms
containing SAIB than without. Decladinose clarithromycin is much more likely to be formed in
the acidic environment of the stomach, suggesting that the dosage forms containing SAIB are
retained in the stomach for longer periods of time. Further studies should be conducted to
confirm this finding. In addition, all of the results for the clarithromycin study show that the
clarithromycin blood levels are more controlled, i.e. more reproducible, when SAIB is included in
the dosage form.
Finally, the dosage form imaging studies were not conclusive in confirming results from
other studies that dosage forms containing SAIB persist for longer periods of time. Though
some dosage forms containing SAIB were longer-lived than some without SAIB, this observation
was not consistent. It is possible that inconsistencies in dosage form preparation led to this
result. Future work should be directed at improving dosage form preparation and making the
preparation process more consistent. It could not be determined whether or not SAIB
promotes gastric retention of the dosage form.
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